Israeli - Kiingereza - Ministry of Health

kamada ltd, israel - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg/ml - bevacizumab - - bevacizumab kamada in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.- bevacizumab kamada in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. - bevacizumab kamada in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer.- bevacizumab kamada in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.- bevacizumab kamada as a single agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.- bevacizumab kamada in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).- bevacizumab kamada in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.- bevacizumab kamada in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents - bevacizumab kamada in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix.- bevacizumab kamada in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations.

Marekani - Kiingereza - NLM (National Library of Medicine)

genentech, inc. - bevacizumab (unii: 2s9zzm9q9v) (bevacizumab - unii:2s9zzm9q9v) - bevacizumab 100 mg in 4 ml - avastin, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mcrc). avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mcrc who have progressed on a first-line bevacizumab product-containing regimen. limitations of use : avastin is not indicated for adjuvant treatment of colon cancer [see clinical studies (14.2)]. avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (nsclc). avastin is indicated for the treatment of recurrent glioblastoma (gbm) in adults. avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mrcc). avastin, in combination with paclitaxel and cisplatin

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

daiichi sankyo company, limited - bevacizumab (genetical recombination) [bevacizumab biosimilar 2] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

daiichi sankyo company, limited - bevacizumab (genetical recombination) [bevacizumab biosimilar 2] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - bevacizumab(genetical recombination)[bevacizumab biosimilar 3] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

pfizer pharmaceuticals inc. - bevacizumab(genetical recombination)[bevacizumab biosimilar 1] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - bevacizumab(genetical recombination)[bevacizumab biosimilar 3] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

pfizer pharmaceuticals inc. - bevacizumab(genetical recombination)[bevacizumab biosimilar 1] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

nippon kayaku - bevacizumab (genetical recombination) [bevacizumab biosimilar 4] - injection

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

nippon kayaku - bevacizumab (genetical recombination) [bevacizumab biosimilar 4] - injection